Partisan Perspectives in the Medical Literature: A Study of High Frequency Editorialists Favoring Hormone Replacement Therapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Unfavorable results of major studies have led to a large shrinkage of the market for hormone replacement therapy (HRT) in the last 6 years. Some scientists continue to strongly support the use of HRT.
We analyzed a sample of partisan editorializing articles on HRT to examine their arguments, the reporting of competing interests, the journal venues and their sponsoring societies.
Through Thomson ISI database, we selected articles without primary data written by the five most prolific editorialists that addressed clinical topics pertaining to HRT and that were published in regular journal issues in 2002–2008.
We recorded the number of articles with a partisan stance and their arguments, the number of partisan articles that reported conflicting interests, and the journal venues and their sponsoring societies publishing the partisan editorials.
We analyzed 114 eligible articles (58 editorials, 16 guidelines, 37 reviews, 3 letters), of which 110 (96%) had a partisan stance favoring HRT. Typical arguments were benefits for menopausal and related symptoms (64.9%), criticism of unfavorable studies (78.9%), preclinical data that showed favorable effects of HRT (50%), and benefits for major outcomes such as osteoporosis and fractures (49.1%), cardiovascular disease (31.6%), dementia (24.6%) or colorectal cancer (20.2%), but also even breast cancer (4.4%). All 5 prolific editorialists had financial relationships with hormone manufacturers, but these were reported in only 6 of the 110 partisan articles. Four journals published 15–37 partisan articles each. The medical societies of these journals reported on their websites that several pharmaceutical companies sponsored them or their conferences.
There is a considerable body of editorializing articles favoring HRT use and very few of these articles report conflicts of interest. Full disclosure of conflicts of interest is needed, especially for articles without primary data.
- Wilson D. Wyeth’s Use of Medical Ghostwriters Questioned. New York Times. December 13, 2008:B1 (Accessed on March 2010 at http://www.nytimes.com/2008/12/13/business/13wyeth.html?_r=1&ref=business)
- Rossouw, JE, Anderson, GL, Prentice, RL (2002) Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288: pp. 321-333 CrossRef
- Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: pp. 419-427 CrossRef
- Hersh, AL, Stefanick, ML, Stafford, RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291: pp. 47-53 CrossRef
- Watson, J, Wise, L, Green, J (2007) Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 63: pp. 843-849 CrossRef
- Summary of balancing risks and benefits. Obstet Gynecol 104: pp. 128S-129S CrossRef
- Mosca, L, Appel, LJ, Benjamin, EJ (2004) Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109: pp. 672-693 CrossRef
- Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause. 2004;11:589–600.
- Wathen, CN, Feig, DS, Feightner, JW, Abramson, BL, Cheung, AM (2004) Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 170: pp. 1535-1537
- Tatsioni, A, Bonitsis, NG, Ioannidis, JP (2007) Persistence of contradicted claims in the literature. JAMA 298: pp. 2517-2526 CrossRef
- Siontis, GC, Tatsioni, A, Katritsis, DG, Ioannidis, JP (2009) Persistent reservations against contradicted percutaneous coronary intervention indications: citation content analysis. Am Heart J 157: pp. 695-701 CrossRef
- Angell, M (2004) Drug companies. Oxford University Press, New York
- Rothman, DJ, McDonald, WJ, Berkowitz, CD (2009) Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 301: pp. 1367-1372 CrossRef
- Sniderman, AD, Furberg, CD (2009) Why guidelinemaking requires reform. JAMA 301: pp. 429-431 CrossRef
- Steinbrook, R (2008) Financial support of continuing medical education. JAMA 299: pp. 1060-1062 CrossRef
- Rothman, DJ (2008) Academic medical centers and financial conflicts of interest. JAMA 299: pp. 695-697 CrossRef
- Ehringhaus, SH, Weissman, JS, Sears, JL, Goold, SD, Feibelmann, S, Campbell, EG (2008) Responses of medical schools to institutional conflicts of interest. JAMA 299: pp. 665-671 CrossRef
- Podolsky, SH, Greene, JA (2008) A historical perspective of pharmaceutical promotion and physician education. JAMA 300: pp. 831-833 CrossRef
- Campbell, EG, Gruen, RL, Mountford, J, Miller, LG, Cleary, PD, Blumenthal, D (2007) A national survey of physician-industry relationships. N Engl J Med 356: pp. 1742-1750 CrossRef
- Relman, AS (2007) Medical professionalism in a commercialized health care market. JAMA 298: pp. 2668-2670 CrossRef
- Brennan, TA, Rothman, DJ, Blank, L (2006) Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 295: pp. 429-433 CrossRef
- Peppercorn, J, Blood, E, Winer, E, Partridge, A (2007) Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109: pp. 1239-1246 CrossRef
- Vlad, SC, LaValley, MP, McAlindon, TE, Felson, DT (2007) Glucosamine for pain in osteoarthritis: why do trial results differ?. Arthritis Rheum 56: pp. 2267-2277 CrossRef
- Ioannidis, JP (2005) Why most published research findings are false. PLoS Med 2: pp. e124 CrossRef
- Ioannidis, JP (2008) Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?. Philos Ethics Humanit Med 3: pp. 14 CrossRef
- Stelfox, HT, Chua, G, O’Rourke, K, Detsky, AS (1998) Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338: pp. 101-106 CrossRef
- Choudhry, NK, Stelfox, HT, Detsky, AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287: pp. 612-617 CrossRef
- Angell, M, Kassirer, JP (1996) Editorials and conflicts of interest. N Engl J Med 335: pp. 1055-1056 CrossRef
- Kassirer, JP, Angell, M (1993) Financial conflicts of interest in biomedical research. N Engl J Med 329: pp. 570-571 CrossRef
- Steinman, MA, Bero, LA, Chren, MM, Landefeld, CS (2006) Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145: pp. 284-293
- Healy, D, Cattell, D (2003) Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 183: pp. 22-27 CrossRef
- Ross, JS, Hill, KP, Egilman, DS, Krumholz, HM (2008) Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 299: pp. 1800-1812 CrossRef
- Gøtzsche, PC, Hróbjartsson, A, Johansen, HK, Haahr, MT, Altman, DG, Chan, AW (2007) Ghost authorship in industry-initiated randomised trials. PLoS Med 4: pp. e19 CrossRef
- Conflict of Interest in Medical Research, Education and Practice. Bernard Lo and Marilyn J. Eds. Report prepared by the Committee on Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: Institute of Medicine. National Academy Press; April 28, 2009.
- Partisan Perspectives in the Medical Literature: A Study of High Frequency Editorialists Favoring Hormone Replacement Therapy
Journal of General Internal Medicine
Volume 25, Issue 9 , pp 914-919
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- hormone replacement therapy
- postmenopausal women
- Industry Sectors
- Author Affiliations
- 1. Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, 45110, Greece
- 3. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA
- 2. Biomedical Research Institute, Foundation for Research and Technology-Hellas, Ioannina, Greece